Clinical Trial

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effective and safer.
Trial Details
NCT Number NCT07365410
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
Enrollment 60 participants
Start Date 2026-01
Primary Completion 2026-05 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-26